D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 42.33 CNY -1.17% Market Closed
Market Cap: 17.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Net Margin
Dizal Jiangsu Pharmaceutical Co Ltd

-632.9%
Current
-4 541%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-632.9%
=
Net Income
-1.1B
/
Revenue
172.6m

Net Margin Across Competitors

Country CN
Market Cap 17.3B CNY
Net Margin
-633%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.8B EUR
Net Margin
-14%
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
17.3B CNY
Industry
Biotechnology

In the heart of China's vibrant pharmaceutical landscape lies Dizal Jiangsu Pharmaceutical Co Ltd, a dynamic company at the forefront of innovative drug development. Founded as a joint venture with a vision to bridge unmet medical needs, Dizal focuses primarily on oncology and immunology. This firm thrives on its strong pipeline of next-generation therapies, nurtured by a robust research and development arm. Collaborating with global biotech entities, it leverages cutting-edge technologies and deep scientific acumen to create breakthrough biologic and small molecule drugs that hold the potential to transform patient outcomes. Dizal’s research hubs are bustling with expert scientists dedicated to translating scientific discoveries into tangible therapies, positioning the company as a significant player in the biopharmaceutical sector. Dizal makes its money through a well-orchestrated stream of activities emphasizing strategic partnerships, intellectual property licensing, and product sales. By forging alliances with industry giants for co-development and commercialization, the company ensures a wider reach and impactful roll-out of its products. Additionally, the progressive monetization strategy of awarding patents and licenses in conjunction with its proprietary compounds enables a steady revenue inflow. This symbiotic model not only empowers Dizal to fund further innovative research but also reinforces its stature within the competitive arena of drug development. As healthcare demands continuously evolve, Dizal’s revenue generation strategies remain agile, marrying scientific ingenuity with strategic foresight.

Intrinsic Value
29.34 CNY
Overvaluation 31%
Intrinsic Value
Price
D

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-632.9%
=
Net Income
-1.1B
/
Revenue
172.6m
What is the Net Margin of Dizal Jiangsu Pharmaceutical Co Ltd?

Based on Dizal Jiangsu Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of -632.9%.